The project aims at initiating and implementing a Phase II trial in order to investigate whether an already approved diagnostic drug can be used for the detection of kidney cancer. Diagnostics could in a conclusive way contribute to a more detailed analysis of the metastasis in these patients than is currently possible. This would mean that systemic therapy could be introduced earlier, which in turn can result in patients surviving longer.
Menu